Exposure–response relationship of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Documenti analoghi

• Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen
  di: Ya‐Ping Tu, et al.
  Pubblicazione: (2024)
• Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings
  di: Monica Jung, et al.
  Pubblicazione: (2026)
• Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria
  di: Valérie Cosson, et al.
  Pubblicazione: (2025)
• Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus
  di: Junyi Wu, et al.
  Pubblicazione: (2024)
• Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies
  di: Roxanne C. Jewell, et al.
  Pubblicazione: (2024)